Saturated fatty acids enhance osteoclast survival.
Hyperlipidemia and marrow fat are associated with lowering bone density in vivo, suggesting that lipid contributes to bone loss. Using bone marrow-derived macrophages, we investigated the effect of saturated fatty acids (SFA) on osteoclastogenesis. The level of free fatty acids and adiposity in bone marrow was significantly elevated in obese mice. SFA increased osteoclast (OC) survival by preventing apoptosis. SFA caused the production of MIP-1alpha and led to activation of nuclear factor (NF)-kappaB in the OC. The absence of Toll-like receptor 4 (TLR4) or myeloid differentiation factor 88 (MyD88) abolished the survival effect of SFA on OC.
Oh
So-Ra
SR
Department of Biological Sciences (BK21 Program), University of Ulsan, Ulsan 680-749, Korea.
Sul
Ok-Joo
OJ
Kim
Youn-Young
YY
Kim
Hye-Jin
HJ
Yu
Rina
R
Suh
Jae-Hee
JH
Choi
Hye-Seon
HS
D000818:Animals; D001853:Bone Marrow / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D054405:Chemokine CCL3 / Q000096:biosynthesis; D005227:Fatty Acids / Q000378:metabolism / Q000494:pharmacology*; D055786:Gene Knockout Techniques; D008297:Male; D051379:Mice; D053594:Myeloid Differentiation Factor 88 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D009765:Obesity / Q000378:metabolism; D010010:Osteoclasts / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D051197:Toll-Like Receptor 4 / Q000172:deficiency / Q000235:genetics / Q000378:metabolism
D054405:Chemokine CCL3; D005227:Fatty Acids; D053594:Myeloid Differentiation Factor 88; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4
J Bone Miner Res. 2008 Nov;23(11):1722-30
18597639
J Immunol. 2002 Aug 1;169(3):1516-23
12133979
J Bone Miner Res. 2006 Dec;21(12):1907-12
17002586
J Immunol. 2004 Aug 1;173(3):2084-90
15265944
Endocrinology. 2008 Nov;149(11):5688-95
18617622
J Intern Med. 2007 Oct;262(4):408-14
17875176
Bone. 2005 May;36(5):840-53
15794931
J Clin Invest. 2001 Dec;108(12):1833-41
11748267
FASEB J. 2004 Aug;18(11):1282-4
15208271
J Periodontol. 2007 Mar;78(3):559-65
17335381
J Periodontol. 2006 Mar;77(3):350-6
16512748
Immunol Res. 2000;21(2-3):49-54
10852101
Cell Death Differ. 2003 Oct;10(10):1165-77
14502240
J Immunol. 2003 Apr 1;170(7):3688-95
12646634
J Biol Chem. 2001 May 18;276(20):16683-9
11278967
J Exp Med. 1992 Aug 1;176(2):485-94
1380063
J Biol Chem. 1998 Oct 23;273(43):28355-9
9774460
Bone. 2007 Jun;40(6):1581-7
17409043
J Lipid Res. 2006 Aug;47(8):1739-48
16702601
Endocrinol Metab Clin North Am. 2008 Sep;37(3):635-46, viii-ix
18775356
Infect Immun. 1996 Jul;64(7):2371-80
8698454
J Magn Reson Imaging. 2005 Aug;22(2):279-85
16028245
Immunity. 1998 Jul;9(1):143-50
9697844
Mol Cell Endocrinol. 2001 Apr 25;175(1-2):81-92
11325518
Osteoporos Int. 2005 Dec;16(12):1975-81
16167087
Methods. 2001 Dec;25(4):402-8
11846609
Blood. 2000 Jul 15;96(2):671-5
10887133
J Intern Med. 2006 Jun;259(6):598-605
16704561
J Biol Chem. 2007 Nov 30;282(48):35279-92
17916553
Exp Hematol. 2007 Jul;35(7):1100-8
17588479
J Clin Invest. 2005 May;115(5):1111-9
15864338
J Clin Pathol. 2002 Sep;55(9):693-8
12195001
J Clin Endocrinol Metab. 2004 Sep;89(9):4246-53
15356016
J Bone Miner Res. 2001 Jan;16(1):182-8
11149483
Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):e6-10
14670933
Endocr Rev. 1996 Aug;17(4):308-32
8854048
Immunity. 1999 Jul;11(1):115-22
10435584